RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07401537, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Advanced (locally recurrent inoperable or metastatic) TNBC confirmed by histology or cytology, defined as ER-negative, PR-negative, and HER2-negative.

    Inclusion criterion 3

  3. Have received first-line standard immunotherapy combined with chemotherapy or immunotherapy combined with ADC and completed 6 cycles, with the last dose administered no more than 28 days before randomization.

    Inclusion criterion 5

    The therapeutic efficacy was confirmed as CR, PR or SD after 6-cycle standard treatment according to the RECIST v1.1 criteria.

    Inclusion criterion 6

    Presence of grade ≥3 toxicities related to prior treatments that restrict the continuation of maintenance therapy.

    Exclusion criterion 11

    Use of systemic glucocorticoids at a dose exceeding 10 mg/day of prednisone equivalent within 14 days prior to the administration of study drugs, or planned long-term use of the above dose during the study period (topical, inhaled, or short-term (≤7 days) pulse doses ≤10 mg/day of prednisone equivalent, or physiological dose replacement therapy are allowed for inclusion).

    Exclusion criterion 15

    Need for use of any immunosuppressants within 14 days prior to the administration of study drugs or planned use during the study period.

    Exclusion criterion 16

  4. Concomitant other malignant tumors with progression within the recent 5 years or requiring active treatment (excluding adequately treated and controlled carcinoma in situ and non-melanoma skin cancer).

    Exclusion criterion 2

    History of immunodeficiency, including HIV positivity, active HBV/HCV infection, other acquired or congenital immunodeficiency diseases, and history of organ or allogeneic stem cell transplantation.

    Exclusion criterion 12

  5. Female subjects of childbearing potential must agree to use highly effective contraceptive measures starting at least 7 days before the first dose and continuing until 24 weeks after the last dose. The serum pregnancy test result must be negative within 7 days prior to the first dose.

    Inclusion criterion 13

    Pregnant or lactating women, or women of childbearing potential who refuse to accept contraceptive measures.

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07401537, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary consent to participate in this study and signing of the informed consent form.
  • The age of the signatory of the informed consent form should be ≥18 years old and ≤70 years old.
  • Advanced (locally recurrent inoperable or metastatic) TNBC confirmed by histology or cytology, defined as ER-negative, PR-negative, and HER2-negative.
  • PD-L1 IHC detection in tumor tissue with a CPS score ≥1.
  • Have received first-line standard immunotherapy combined with chemotherapy or immunotherapy combined with ADC and completed 6 cycles, with the last dose administered no more than 28 days before randomization.
  • The therapeutic efficacy was confirmed as CR, PR or SD after 6-cycle standard treatment according to the RECIST v1.1 criteria.
  • Plan to continue receiving immunotherapy.
  • An Eastern Cooperative Oncology Group performance-status score of 0 or 1.
  • The expected survival period exceeds 12 weeks.
  • Adequate organ function:.
  • No mental or intellectual abnormalities.
  • Willing and able to comply with the trial protocol during the trial period.
  • Female subjects of childbearing potential must agree to use highly effective contraceptive measures starting at least 7 days before the first dose and continuing until 24 weeks after the last dose. The serum pregnancy test result must be negative within 7 days prior to the first dose.

Exclusion Criteria:

  • Untreated active brain metastases or meningeal metastases.
  • Concomitant other malignant tumors with progression within the recent 5 years or requiring active treatment (excluding adequately treated and controlled carcinoma in situ and non-melanoma skin cancer).
  • Concomitant severe non-malignant diseases that would affect the patient's compliance or put the patient at risk.
  • Concomitant active infection.
  • Receiving other anti-tumor therapies or participating in other interventional clinical trials.
  • Inflammatory breast cancer.
  • Dementia, intellectual disability, or any mental disorders that hinder the understanding of the informed consent form.
  • History of allergic reactions to any components of the study drugs or existing contraindications to their use.
  • Presence of any active autoimmune diseases or history of autoimmune diseases.
  • Presence of poorly controlled clinical cardiac symptoms or diseases, such as:1) Heart failure of NYHA class II or above;2) Unstable angina pectoris;3) Myocardial infarction occurring within 1 year;4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
  • Presence of grade ≥3 toxicities related to prior treatments that restrict the continuation of maintenance therapy.
  • History of immunodeficiency, including HIV positivity, active HBV/HCV infection, other acquired or congenital immunodeficiency diseases, and history of organ or allogeneic stem cell transplantation.
  • Vaccination with live vaccines within 4 weeks prior to the administration of study drugs or planned vaccination during the study period.
  • Prior administration of irinotecan, topotecan, or any other topoisomerase I inhibitors (including investigational topoisomerase I inhibitors), or known history of allergies to the above-mentioned drugs.
  • Use of systemic glucocorticoids at a dose exceeding 10 mg/day of prednisone equivalent within 14 days prior to the administration of study drugs, or planned long-term use of the above dose during the study period (topical, inhaled, or short-term (≤7 days) pulse doses ≤10 mg/day of prednisone equivalent, or physiological dose replacement therapy are allowed for inclusion).
  • Need for use of any immunosuppressants within 14 days prior to the administration of study drugs or planned use during the study period.
  • Pregnant or lactating women, or women of childbearing potential who refuse to accept contraceptive measures.
  • Patients who are difficult or impossible to follow up.
  • Subjects judged by the investigator to have conditions that may affect compliance or other circumstances making them unsuitable for inclusion.

Quoted from ClinicalTrials.gov, NCT07401537, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07401537, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07401537